NRG-BR002

A Phase IIR/III Trial of Standard of Care Therapy with or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer

Principal Investigator

Steven Chmura

Status

Disease Site

Breast [BR] Breast

Phase

II/III

Developmental Therapeutics

No

Primary Objective

Phase II-R:  To determine whether ablation (through SBRT and/or surgical resection of all known metastases) in oligometastatic breast cancer patients provides a sufficient signal for improved progression-free survival (PFS) to warrant full accrual to the Phase III portion of the trial.

Phase III:  To determine whether ablation (through SBRT and/or surgical resection of all known metastases) in oligometastatic breast cancer patients significantly improves overall survival (OS) 

Patient Population

Patients with locally controlled metastatic breast cancer with≤ 4 metastases in permissible metastatic sites seen on standard imaging within 60 days prior to registration ( See  Protocol eligibility section 3.2.3 ); and at least 1 pathologically confirmed visualized on CT or PET/CT.

Target Accrual

548